PL372398A1 - Zastosowanie inhibitorów IL-18 do leczenia i/lub zapobiegania chorobom naczyń obwodowych - Google Patents

Zastosowanie inhibitorów IL-18 do leczenia i/lub zapobiegania chorobom naczyń obwodowych

Info

Publication number
PL372398A1
PL372398A1 PL03372398A PL37239803A PL372398A1 PL 372398 A1 PL372398 A1 PL 372398A1 PL 03372398 A PL03372398 A PL 03372398A PL 37239803 A PL37239803 A PL 37239803A PL 372398 A1 PL372398 A1 PL 372398A1
Authority
PL
Poland
Prior art keywords
prevention
treatment
peripheral vascular
vascular diseases
inhibitors
Prior art date
Application number
PL03372398A
Other languages
English (en)
Other versions
PL207303B1 (pl
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Applied Research Systems Ars Holding N.V.
Institut National De La Sante Et De La Recherche Medicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V., Institut National De La Sante Et De La Recherche Medicale filed Critical Applied Research Systems Ars Holding N.V.
Publication of PL372398A1 publication Critical patent/PL372398A1/pl
Publication of PL207303B1 publication Critical patent/PL207303B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL372398A 2002-03-22 2003-03-13 Zastosowanie inhibitora IL-18 do leczenia i/lub zapobiegania chorobom naczyń obwodowych i zastosowanie wektorów ekspresyjnych PL207303B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02100290 2002-03-22

Publications (2)

Publication Number Publication Date
PL372398A1 true PL372398A1 (pl) 2005-07-25
PL207303B1 PL207303B1 (pl) 2010-11-30

Family

ID=28051827

Family Applications (1)

Application Number Title Priority Date Filing Date
PL372398A PL207303B1 (pl) 2002-03-22 2003-03-13 Zastosowanie inhibitora IL-18 do leczenia i/lub zapobiegania chorobom naczyń obwodowych i zastosowanie wektorów ekspresyjnych

Country Status (27)

Country Link
US (2) US9592267B2 (pl)
EP (1) EP1487541B1 (pl)
JP (1) JP4885424B2 (pl)
KR (1) KR20050004809A (pl)
CN (1) CN100540058C (pl)
AR (1) AR039103A1 (pl)
AT (1) ATE414556T1 (pl)
AU (1) AU2003219162B2 (pl)
BR (1) BRPI0308663B8 (pl)
CA (1) CA2478855C (pl)
CY (1) CY1108748T1 (pl)
DE (1) DE60324777D1 (pl)
DK (1) DK1487541T3 (pl)
EA (1) EA008495B1 (pl)
ES (1) ES2314191T3 (pl)
HR (1) HRP20040758B1 (pl)
IL (2) IL164211A0 (pl)
ME (1) ME00548B (pl)
MX (1) MXPA04009135A (pl)
NO (1) NO336226B1 (pl)
PL (1) PL207303B1 (pl)
PT (1) PT1487541E (pl)
RS (1) RS51755B (pl)
SI (1) SI1487541T1 (pl)
UA (1) UA80275C2 (pl)
WO (1) WO2003080104A2 (pl)
ZA (1) ZA200407022B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
BRPI0308663B8 (pt) 2002-03-22 2021-05-25 Applied Res Systems Ars Holding N V uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
US9050365B2 (en) * 2004-04-19 2015-06-09 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
AU2006256763B2 (en) 2005-06-10 2012-08-02 Ares Trading S.A. Process for the purification of IL-18 binding protein
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
EP2567692B1 (en) 2008-02-27 2016-04-06 Biomet Biologics, LLC Use of a device for obtaining interleukin-1 receptor antagonist rich solutions
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP3045171A1 (en) 2009-06-24 2016-07-20 Strategic Science & Technologies, LLC Topical composition
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9763875B2 (en) 2009-08-27 2017-09-19 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
KR101603001B1 (ko) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
CN105920603B (zh) 2010-12-29 2022-02-11 战略科学与技术有限责任公司 勃起功能障碍和其它适应症的治疗
CN103442723A (zh) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9895418B2 (en) * 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9833474B2 (en) 2013-11-26 2017-12-05 Biomet Biologies, LLC Methods of mediating macrophage phenotypes
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
DE60041432D1 (de) * 1999-11-16 2009-03-12 Hayashibara Biochem Lab Antikörper spezifisch für den Interleukin-18 Vorläufer
CZ300792B6 (cs) * 2000-05-05 2009-08-12 Applied Research Systems Ars Holding N. V. Farmaceutický prostredek
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
BRPI0308663B8 (pt) 2002-03-22 2021-05-25 Applied Res Systems Ars Holding N V uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas

Also Published As

Publication number Publication date
ATE414556T1 (de) 2008-12-15
US20060233799A1 (en) 2006-10-19
ME00548B (me) 2011-10-10
EP1487541A2 (en) 2004-12-22
JP2005520852A (ja) 2005-07-14
HK1075422A1 (zh) 2005-12-16
NO336226B1 (no) 2015-06-22
EA200401240A1 (ru) 2005-02-24
HRP20040758A2 (en) 2005-02-28
UA80275C2 (en) 2007-09-10
US9592267B2 (en) 2017-03-14
CN1655845A (zh) 2005-08-17
JP4885424B2 (ja) 2012-02-29
KR20050004809A (ko) 2005-01-12
EP1487541B1 (en) 2008-11-19
MXPA04009135A (es) 2004-12-07
WO2003080104A2 (en) 2003-10-02
BR0308663A (pt) 2005-01-25
IL164211A0 (en) 2005-12-18
EA008495B1 (ru) 2007-06-29
DE60324777D1 (de) 2009-01-02
AU2003219162A1 (en) 2003-10-08
PL207303B1 (pl) 2010-11-30
US20100291028A1 (en) 2010-11-18
WO2003080104A3 (en) 2004-03-04
PT1487541E (pt) 2008-12-10
AR039103A1 (es) 2005-02-09
DK1487541T3 (da) 2009-01-19
SI1487541T1 (sl) 2009-02-28
HRP20040758B1 (hr) 2012-10-31
CA2478855C (en) 2013-12-17
IL164211A (en) 2011-07-31
ES2314191T3 (es) 2009-03-16
CY1108748T1 (el) 2014-04-09
AU2003219162B2 (en) 2008-01-03
US9566313B2 (en) 2017-02-14
NO20044459L (no) 2004-10-20
RS81504A (sr) 2006-12-15
CN100540058C (zh) 2009-09-16
CA2478855A1 (en) 2003-10-02
ZA200407022B (en) 2006-06-28
BRPI0308663B1 (pt) 2019-07-16
BRPI0308663B8 (pt) 2021-05-25
RS51755B (sr) 2011-12-31

Similar Documents

Publication Publication Date Title
PL372398A1 (pl) Zastosowanie inhibitorów IL-18 do leczenia i/lub zapobiegania chorobom naczyń obwodowych
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
CY1114448T1 (el) Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας
WO2002069945A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren
YU82602A (sh) Korišćenje il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze
SE0200667D0 (sv) Novel use of cytokine inhibitors
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
GB0020504D0 (en) Therapeutic method
AU2003250190A1 (en) Combination of an aromatase inhibitor with a bisphosphonate
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
SG145773A1 (en) Therapeutic treatment
WO2004037233A3 (en) Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
YU11904A (sh) Upotreba inhibitora il-18 kod poremećaja preosetljivosti
PL375354A1 (pl) Zastosowanie treosulfanu i jego pochodnych do leczenia stwardnienia rozsianego
WO2007077454A3 (en) A therapeutic composition comprising an inhibitor of an hsp 90 protein
WO2004012732A3 (en) Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy
ZA200503703B (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
MXPA04011019A (es) Combinacion de un inhibidor de la bomba de protones y un agente respiratorio, para el tratamiento de trastornos de las vias respiratorias.
WO2004035030A3 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
AU2003216927A1 (en) Novel therapeutic composition for the prevention and treatment of hiv-1 infection in humans
AU2003209489A1 (en) Medical use of captopril for the treatment and prophylaxis of cancer
AU2002222500A1 (en) Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
GEP20043317B (en) Ointment for Treatment of Purulent Diseases, Festering Wounds and Burns